These findings suggest a potential role for sGFAP as biomarker for disease severity and future disease activity in patients with AQP4-IgG⁺ NMOSD in phases of clinical remission.
No takes yet. Share an insight, caveat, or question.
Schindler et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: